Head to Head Contrast: Immune Pharmaceuticals (IMNP) vs. Eyegate Pharmaceuticals (EYEG)
Immune Pharmaceuticals (NASDAQ: IMNP) and Eyegate Pharmaceuticals (NASDAQ:EYEG) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.
Volatility & Risk
Immune Pharmaceuticals has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500. Comparatively, Eyegate Pharmaceuticals has a beta of 3.31, indicating that its stock price is 231% more volatile than the S&P 500.
This table compares Immune Pharmaceuticals and Eyegate Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Immune Pharmaceuticals and Eyegate Pharmaceuticals’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Immune Pharmaceuticals||N/A||N/A||-$12.48 million||($6.87)||-0.21|
|Eyegate Pharmaceuticals||$767,481.00||27.35||-$13.31 million||($1.30)||-0.94|
Immune Pharmaceuticals has higher revenue, but lower earnings than Eyegate Pharmaceuticals. Eyegate Pharmaceuticals is trading at a lower price-to-earnings ratio than Immune Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
3.4% of Immune Pharmaceuticals shares are held by institutional investors. Comparatively, 13.0% of Eyegate Pharmaceuticals shares are held by institutional investors. 6.7% of Immune Pharmaceuticals shares are held by company insiders. Comparatively, 24.6% of Eyegate Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This is a summary of current ratings and target prices for Immune Pharmaceuticals and Eyegate Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Immune Pharmaceuticals currently has a consensus target price of $3.00, suggesting a potential upside of 111.27%. Eyegate Pharmaceuticals has a consensus target price of $7.33, suggesting a potential upside of 501.09%. Given Eyegate Pharmaceuticals’ higher possible upside, analysts plainly believe Eyegate Pharmaceuticals is more favorable than Immune Pharmaceuticals.
Eyegate Pharmaceuticals beats Immune Pharmaceuticals on 8 of the 11 factors compared between the two stocks.
About Immune Pharmaceuticals
Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.
About Eyegate Pharmaceuticals
Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
Receive News & Stock Ratings for Immune Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.